John Ratliff Named CEO of AMRI
December 2, 2019
ALBANY, N.Y.–(BUSINESS WIRE)–AMRI, a leading global pharmaceutical contract research, development and manufacturing organization, today announced that John Ratliff has been named as chief executive officer, effective today, Dec. 2, 2019. Ratliff succeeds Michael Mulhern, who has been appointed as chairman of the AMRI Board of Directors.
“I am excited to join AMRI and look forward to collaborating with a very talented group of professionals,” said Ratliff. “Together we will strengthen AMRI’s position as a market leader and strategic partner for pharmaceutical and biotech companies worldwide. Michael and his team have accomplished a great deal, and I look forward to leading AMRI through its next phase of growth.”
Ratliff previously served as CEO of Covance, a $4.3 billion revenue drug development business within LabCorp, and has more than two decades of experience in the pharmaceutical and life sciences industry. Prior to LabCorp, he served as CEO of HUYA Biosciences, a global biopharma innovation company. Ratliff also served in various roles at Quintiles, the leading global pharmaceutical services provider, including chief financial officer, chief operating officer, and president. Ratliff graduated from The Georgia Institute of Technology with a Bachelor of Science degree in industrial and systems engineering and holds an MBA from Duke University.
“I am extremely proud of the AMRI team and the success that we have achieved enhancing the company’s capabilities, operational excellence and strategic positioning over the past two years,” said Mulhern. “I am thrilled to have John join the organization and believe that he will do an excellent job leading the team and driving significant growth at AMRI over the coming years.”
AMRI, a global contract research and manufacturing organization, partners with the pharmaceutical and biotechnology industries to improve patient outcomes and quality of life. With locations in North America, Europe and Asia, AMRI’s team combines scientific expertise and market-leading technology to provide a complete suite of solutions in Discovery, Development, Analytical Services, API Manufacturing and Drug Product. For more information about AMRI, visit www.amriglobal.com.
More from Curia
September 15, 2023
Curia Supports Replicate Bioscience’s Phase 1 Clinical Trial of Novel Next-Generation RNA Vaccine
Supply of drug substance manufactured under cGMP supports first-in-human clinical study for RBI-4000 novel self-replicating RNA (srRNA)